| Dr John Patrick Mildenberger, PHARMD | |
|
1000 Pole Creek Xing, Sidney, NE 69162-2901 | |
| (308) 254-7268 | |
| Not Available |
| Full Name | Dr John Patrick Mildenberger |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 1000 Pole Creek Xing, Sidney, Nebraska |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497234926 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 14298 (Nebraska) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Patrick Mildenberger, PHARMD 1308 S 11th Ave, Sterling, CO 80751-4427 Ph: () - | Dr John Patrick Mildenberger, PHARMD 1000 Pole Creek Xing, Sidney, NE 69162-2901 Ph: (308) 254-7268 |
News Archive
Metabolon, the leader in metabolomics, biomarker discovery and analysis, announces the publication of "Metabolomic Distinction and Insights into the Pathogenesis of Human Primary Dilated Cardiomyopathy", in the European Journal of Clinical Investigation.
The Department of Industrial Relations' Division of Occupational Safety and Health, better known as Cal/OSHA, reminds all California employers to post at their place of business a summary of work-related injuries and illnesses that occurred during 2010.
US-based Life Technologies Corporation, a provider of innovative life science solutions, announced today that it has launched a regional distribution hub in Singapore to address strong customer demand in the Asia Pacific regions of India, China, Taiwan, Hong Kong, Korea, South East Asia, Australia and New Zealand.
Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.
Boston Scientific Corporation today announced the execution of a definitive agreement under which Stryker Corporation will acquire Boston Scientific's Neurovascular business. The purchase price is $1.5 billion, payable in cash, of which $1.4 billion is payable at closing and $100 million will be payable following the closing and upon the occurrence of the commercialization of the next-generation Target™ Detachable Coils and the transfer or separation of certain manufacturing facilities, which is anticipated to occur over a period of approximately 24 months.
› Verified 3 days ago
Victoria Brauer, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3001 Silverberg Dr, Sidney, NE 69162 Phone: 308-254-9149 | |
Silvano Axel, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1944 Illinios St, Sidney, NE 69162 Phone: 308-254-4531 Fax: 308-254-1182 | |
Michael Patrick Hicks, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1944 Illinois St, Sidney, NE 69162 Phone: 308-254-4531 | |
Alexander T Kanack, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3001 Silverberg Dr, Sidney, NE 69162 Phone: 308-254-9149 | |
Dr. Emily Johnson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1000 Pole Creek Xing, Sidney, NE 69162 Phone: 308-249-5496 | |
Dr. Jesse Robinson, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1944 Illinois St, Sidney, NE 69162 Phone: 308-254-4767 |